New Medical Technologies

Development

of innovative

technologies in medicine.

The purpose of which is to prevent infection of patients of medical institutions of various profiles with viruses, the effective cure for which has not yet been created.

Read more
Conducting

research

to identify the mechanisms of virus transmission.

Read more
Development

of new

methods

of sterilization and storage of sterile instruments for medical, hairdressing and household purposes.

Read more

About Company

Ovik Mkrtchyan – Founder of New Medical Technologies

Ovik Mkrtchyan is an entrepreneur involved in innovative projects in healthcare and high technology, and the founder of New Medical Technologies (NMT). Ovik Mkrtchyan has authored several of the company’s technological developments and holds multiple patents. Founded by Ovik Mkrtchyan in 2008, the company develops and implements innovative medical solutions to improve the safety and efficiency of clinical processes. New Medical Technologies specialises in creating medical equipment and technologies for sterilising clinical instruments and inactivating viruses, bacteria, and other pathogens. The company’s solutions are aimed at reducing the risk of hospital-acquired infections and adhere to modern international standards for medical safety. Over its years of operation, NMT has conducted more than 120 studies, including research into virus detection and inactivation. These efforts have led to technological solutions that help prevent the transmission of hepatitis B and C, as well as HIV, through medical instruments in healthcare settings. The company also develops and markets specialised equipment based on innovative principles. For instance, NMT’s virus deactivation device is used in various fields, from medicine and science to everyday household applications. Its design accommodates both medical instruments and everyday items such as tableware, shaving accessories, or children’s toys, ensuring high sanitary standards and reducing the spread of bacteria and viruses in any environment – whether at home, in a beauty salon, in a hospital, at a school, in a dining area, or elsewhere. Another key area for NMT is the development and production of the injectable medicinal product Geptrong, used to treat acute and chronic viral hepatitis, intoxications, and related conditions. Both the product and its active ingredient are patented in several countries, with ongoing research into new dosage forms. NMT places particular emphasis on collaboration with medical institutions and healthcare professionals. The company is committed to long-term growth and the international expansion of its solutions, especially in regions with a heightened need for advanced medical technologies.

“Healthcare is, first and foremost, a matter of responsibility to the future. When technologies are developed consciously and grounded in science, they are capable of improving quality of life and reducing risks in areas where the cost of error is particularly high.” – Ovik Mkrtchyan.

About developments

Method for detecting and evaluating the viability of lymphotropic viruses.

The present method of detecting lymphotropic viruses is intended for:
- increasing the reliability of determining the infection of biological media with hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) with lymphotropism;
- excluding false negative reactions when testing donated blood and patients for infection with HBV, HCV or HIV;
- detecting HBV, HCV or HIV in biological material (donor blood, plasma and other blood derivatives) with a concentration of viral particles below the sensitivity threshold of the ELISA and PCR method;
- assessing the viability of viruses after exposure to chemical and physical antiviral factors developed and offered by manufacturers in order to inactivate viruses in practical healthcare.This method has no analogues.

Virus inactivation installation

It is intended for inactivation of viruses on medical instruments (surgical, dental, gynecological, otolaryngological, ophthalmological and others) in medical institutions of various profiles. The effectiveness of the installation has been proven experimentally on viruses of the vaccine strain of polio, Crimean-congohemorrhagic fever virus, influenza, hepatitis B and C, as well as HIV infection. The installation is registered with the Committee on New Medical Devices and Medicines (General Directorate for Quality Control of Medicines and Medical Equipment) and the Uzbek Agency for Standardization, Metrology and Certification (Uzstandart Agency).

Method

The range of applications of the method for detecting and evaluating the viability of lymphotropic HBV, HCV and HIV viruses.

Blood transfusion stations:

to increase the reliability of detection of lymphotropic hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) in biological media (donor blood, plasma and other components) containing viruses in concentrations below the threshold of sensitivity of ELISA or PCR methods.

Diagnostic laboratories:

to increase the reliability and exclude false negative results when testing for HBV, HCV or HIV infection in the blood of donors or patients with virus content in concentrations below the sensitivity threshold of ELISA or PCR methods.

Pharmaceutical companies:

to assess the viability of HBV, HCV or HIV viruses after exposure to chemical and physical antiviral factors developed and offered by manufacturers in order to inactivate viruses at various facilities.

The method creates the opportunity:

objectively evaluate the effect of chemical or physical factors on the viability (pathogenicity) of lymphotropic viruses.

Allows to eliminate errors

in the diagnosis of patients, when testing donated blood and its components for infection with lymphotropic viruses HBV, HCV or HIV.

Detection

and evaluation of the viability of lymphotropic viruses has no analogues.

Registration and certification documents for installation

According to this method of detecting and assessing the viability of viruses with lymphotropism, the State Patent Office of the Republic of Uzbekistan has issued a patent registered in the State Register of utility models of the Republic of Uzbekistan in Tashkent for No. IAP 04903 dated 06/18/2012.

Patents have been obtained for the invention (according to the method of assessing the viability of lymphotropic viruses) in the European, Eurasian Patent Offices, as well as patent offices of the following countries - Africa, USA, Israel, UAE, India.

Patents and certificates Documents

Certificate

Mass media about us

“Uzbek doctor presented his own development for the treatment of coronavirus. The official proposal on its use has already been sent to the Ministry of Health. Nurmat Otabekov, the Head of the State Inspectorate for Sanitary and Epidemiological Supervision under the Cabinet of Ministers, the Chief State Sanitary Inspector of the Republic, told about the domestic method of combating coronavirus infection and the prospects for its implementation at the briefing in the Information and Mass Communications Agency”

— Source, Podrobno.uz

“People are gullible - we are convinced of this through numerous surveys conducted among clients of beauty salons who regularly perform manicures and pedicures. When women answer questions about the cleanliness of manicure tools and their safety, they choose “I trust the master.”

— Source, Daryo.uz

“New Medical Technologies Company has introduced the SafoNur installation for cold sterilization of medical and cosmetic instruments.”

— Source, Gazeta.uz